Organ-on-Chip Market Size is valued at USD 134.9 Mn in 2023 and is predicted to reach USD 1,424.0 Mn by the year 2031 at an 34.7% CAGR during the forecast period for 2024-2031.
Organ-on-a-chip (OoC) technology, which involves micro-engineered biomimetic systems reflecting the structural and functional characteristics of human tissue, integrates biomaterial technology, cell biology, and engineering into a miniaturized platform. Various models have been successfully developed, including lung-on-a-chip, liver-on-a-chip, kidney-on-a-chip, heart-on-a-chip, intestine-on-a-chip, and skin-on-a-chip.
The FDA has expressed confidence in this innovative technology and has formed partnerships with industries and institutes engaged in its advancement. OoC models have broad applications across scientific domains, such as disease model development, drug screening, toxicology, pathogenesis studies, efficacy testing, and virology. The integration of multiple organ-on-chip modules into a unified body-on-chip device holds significant potential for diagnosis and treatment, particularly in addressing complications from the ongoing COVID-19 pandemic. Consequently, the market demand for developing organ-on-chip devices is expected to skyrocket in the near future.
Organ-on-chip (OoC) technology has thrived due to converging advances in tissue engineering and microfabrication. Progress in cell and tissue engineering has evolved from simple 2D monocultures to sophisticated 3D co-culture systems. Another pivotal factor behind the success of OoCs is microsystems technology, a fabrication approach borrowed from the integrated circuit industry. This technology employs lithographic pattern transfer to create nanometer- and micrometer-scale structures. Milestones in OoC development are closely linked with key technological advancements in microsystems technology, which was initially used in analytical chemistry to create laboratory-on-a-chip devices. This technology has propelled the development of microfluidic systems as well as miniaturized actuators and sensors, enhancing the capabilities of OoCs significantly.
Competitive Landscape
Some of the Major Key Players in the Organ-on-Chip Market are
- Emulate, Inc.
- Mimetas B.V.
- Kirkstall Ltd.
- Numa BioSciences
- AxoSim
- BICO Group AB
- CN Bio Innovations Ltd.
- SynVivo, Inc.
- BEOnchip
- The Charles Stark Draper Laboratory, Inc.
- TissUse GmbH
- InSphero
- Obatala Sciences
- Hesperos, Inc.
- Cherry Biotech
Market Segmentation:
The is segmented based on by application, by offering, by organ type, by end user by region. By application segmented into drug discovery, toxicity testing, and other applications. By offering, the market is categorized into products and services. Based on the organ type, the market is divided into liver-on-a-chip, kidney-on-a-chip, lung-on-a-chip, heart-on-a-chip, brain-on-a-chip, and other organ-on-chip. The end-user, market is divided into pharmaceutical and biotechnology companies, academic and research institutes, the cosmetic industry, and others.
The Drug Discovery Segment is Expected to have the highest growth rate during the forecast period
Based on the by application, the market is divided into drug discovery, toxicity testing, and other applications. Among these, the drug discovery segment is expected to be the highest-growing. Pharmaceutical companies are increasingly adopting Organ-on-Chip (OoC) technology for drug discovery to enhance the efficiency and accuracy of preclinical testing. OoCs provide a more reliable prediction of human responses compared to traditional animal models and 2D cell cultures. Additionally, OoC technology supports the development of personalized medicine by enabling the testing of drug responses on chips populated with cells derived from individual patients. This capability is particularly appealing in the context of precision medicine initiatives, as it allows for tailored therapeutic strategies based on individual patient profiles.
The Liver-on-a-Chip Segment Dominate the Market
Based on the organ type, the market is categorized into liver-on-a-chip, kidney-on-a-chip, lung-on-a-chip, heart-on-a-chip, brain-on-a-chip, and other organ-on-chip. Among these, the liver-on-a-chip segment dominates the market. The liver plays a central role in drug metabolism and detoxification, making liver-on-a-chip devices indispensable for studying drug-induced liver injury (DILI), a major concern in drug development and a leading cause of drug withdrawal from the market. Regulatory agencies, like the FDA, emphasize liver models in their guidance and approvals, further driving the adoption of liver-on-a-chip systems in preclinical testing. Significant research interest and funding are directed towards liver-on-a-chip technology, underscoring its critical role in drug development and disease modeling. This focus on liver models enhances the accuracy of preclinical testing and contributes to safer and more effective drug development.
Asia Pacific is the Fastest-Growing Region During the Forecast Period.
The Asia Pacific region has witnessed significant expansion in its pharmaceutical and biotechnology sectors, with many global pharmaceutical companies establishing R&D centers to leverage cost advantages and skilled labor. This growth is further fueled by increasing healthcare demands driven by a growing population, the rising prevalence of chronic diseases, and an aging demographic. These factors collectively heighten the need for advanced medical technologies, including organ-on-chip systems, to enhance drug development and healthcare solutions in the region.
Recent Developments:
- In April 2024, CN Bio Innovations Ltd. was selected for the SensOoChip Challenge by NC3R, where the goal was to create cutting-edge Heart-on-a-Chip technology.
- In January 2024, CN Bio Innovations Ltd. and Altis Biosystems collaborated to create an in vitro human gut/liver model for advanced absorption, distribution, metabolism, and excretion (ADME) research.
Organ-on-Chip Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 134.9 Mn |
|
Revenue Forecast In 2031 |
USD 1,424.0 Mn |
|
Growth Rate CAGR |
CAGR of 34.7% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
by Application, Offering, Organ Type, End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
Emulate, Inc., Mimetas B.V., Kirkstall Ltd., Numa BioSciences, AxoSim, BICO Group AB, CN Bio Innovations Ltd., SynVivo, Inc., BEOnchip, The Charles Stark Draper Laboratory, Inc., TissUse GmbH, InSphero, Obatala Sciences, Hesperos, Inc.Cherry Biotech. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
